Risk of cellular or antibody-mediated rejection in pediatric kidney transplant recipients with BK polyomavirus replication—an international CERTAIN registry study

期刊论文
出版模式：

开放获取
发表日期：

2024年10月11日

查看全文

Alexander Fichtner,
Jeremy Schmidt,
Caner Süsal,
Andrea Carraro,
Jun Oh,
Matthias Zirngibl,
Sabine König,
Isabella Guzzo,
Lutz T. Weber,
Atif Awan,
Kai Krupka,
Paul Schnitzler,
Hans H. Hirsch,
Burkhard Tönshoff,
Britta Höcker

摘要

Background

In kidney transplant recipients (KTR), BK polyomavirus-associated nephropathy (BKPyVAN) is a major cause of graft loss. To facilitate the clearance of BKPyV-DNAemia, reduction of immunosuppression is currently the treatment of choice but may increase the risk of graft rejection.

Methods

This international CERTAIN study was designed to determine the risk of alloimmune response and graft dysfunction associated with immunosuppression reduction for BKPyV treatment in 195 pediatric KTR.

Results

BKPyV-DNAemia was associated with a more than twofold increased risk of late T cell-mediated rejection (TCMR) (HR 2.22, p = 0.024), of de novo donor-specific HLA antibodies (dnDSA) and/or antibody-mediated rejection (ABMR) (HR 2.64, p = 0.002), and of graft function deterioration (HR 2.73, p = 0.001). Additional independent risk factors for dnDSA/ABMR development were a higher HLA mismatch (HR 2.72, p = 0.006) and re-transplantation (HR 6.40, p = 0.000). Other independent predictors of graft function deterioration were TCMR (HR 3.98, p = 0.003), higher donor age (HR 1.03, p = 0.020), and re-transplantation (HR 3.56, p = 0.013).

Conclusions

These data indicate that reduction of immunosuppression for BKPyV-DNAemia management is associated with increased alloimmune response in pediatric KTR. Therefore, regular dnDSA screening and close monitoring of graft function in case of BKPyV-DNAemia followed by subsequent reduction of immunosuppressive therapy are recommended.

Graphical sbstract